XENE

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

31.870

Open

31.350

VWAP

31.09

Vol

700.78K

Mkt Cap

2.36B

Low

30.560

Amount

21.78M

EV/EBITDA(TTM)

Total Shares

75.47M

1.82B

EV/OCF(TTM)

P/S(TTM)

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-1.121

+33.46%

-1.065

+31.52%

-0.987

+31.55%

Estimates Revision

The market is revising Upward the revenue expectations for Xenon Pharmaceuticals Inc. (XENE) for FY2025, with the revenue forecasts being adjusted by 216.39% over the past three months. During the same period, the stock price has changed by -19.45%.

Revenue Estimates for FY2025

Revise Upward

+216.39%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.58%

In Past 3 Month

Stock Price

Go Down

-19.45%

In Past 3 Month

14 Analyst Rating

80.83% Upside

Wall Street analysts forecast XENE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XENE is 55.64 USD with a low forecast of 47.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

0 Hold

0 Sell

Strong Buy

80.83% Upside

Current: 30.770

Low

47.00

Averages

55.64

High

65.00

80.83% Upside

Current: 30.770

Low

47.00

Averages

55.64

High

65.00

Wells Fargo

Mohit Bansal

Overweight

maintain

$50 -> $47

2025-05-13

Reason

Wells Fargo

Mohit Bansal

Price Target

$50 -> $47

2025-05-13

maintain

Overweight

Reason

Wells Fargo analyst Mohit Bansal lowered the firm's price target on Xenon Pharmaceuticals to $47 from $50 and keeps an Overweight rating on the shares. After enrollment completion was pushed back from the second half of 2024 and now top-line data pushed to early 2026, the firm can see investor concerns around X-TOLE2 program and lack of catalyst this year. Though not statistical significant, Mt. Sinai data was reassuring for MDD activity, Wells adds.

RBC Capital

Brian Abrahams

Outperform

maintain

$58 -> $55

2025-05-13

Reason

RBC Capital

Brian Abrahams

Price Target

$58 -> $55

2025-05-13

maintain

Outperform

Reason

RBC Capital analyst Brian Abrahams lowered the firm's price target on Xenon Pharmaceuticals to $55 from $58 and keeps an Outperform rating on the shares. The slight timeline slippage for the company's first phase 3 azetukalner epilepsy data to early-2026 from the second half of 2025 is slightly disappointing, but the firm still sees a favorable setup going in given solid phase 2 data, good historical translatability, and key opinion leader / survey work as well as the recent branded drug launch precedents that suggest a meaningful $1.2B revenue opportunity, the analyst tells investors in a research note.

Stifel

Buy

maintain

$62 -> $60

2025-05-13

Reason

Stifel

Price Target

$62 -> $60

2025-05-13

maintain

Buy

Reason

Stifel lowered the firm's price target on Xenon Pharmaceuticals to $60 from $62 and keeps a Buy rating on the shares following Q1 earnings. Xenon announced a slight delay to Phase 3 azetukalner topline data, as completion of enrollment is expected in the "next few months," pushing the readout to early 2026 from the second half of 2025. While this delay is "disappointing and could pressure the stock modestly," a few months "isn't a big deal in the grand scheme of things," says the analyst, who still thinks azetukalner is a "blockbuster potential drug" with a high possibility of success in epilepsy and optionality elsewhere.

Goldman Sachs

Paul Choi

Strong Buy

Maintains

$60 → $52

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$60 → $52

2025-04-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$53

2025-02-24

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$53

2025-02-24

Reiterates

Strong Buy

Reason

Deutsche Bank

David Hoang

Strong Buy

Initiates

$67

2025-02-11

Reason

Deutsche Bank

David Hoang

Price Target

$67

2025-02-11

Initiates

Strong Buy

Reason

Deutsche Bank initiated coverage of Xenon Pharmaceuticals with a Buy rating and $67 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Xenon Pharmaceuticals Inc (XENE.O) is -7.36, compared to its 5-year average forward P/E of -12.06. For a more detailed relative valuation and DCF analysis to assess Xenon Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.06

Current PE

-7.36

Overvalued PE

-9.49

Undervalued PE

-14.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.67

Current EV/EBITDA

-4.98

Overvalued EV/EBITDA

-2.37

Undervalued EV/EBITDA

-10.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2109.15

Current PS

0.00

Overvalued PS

5745.55

Undervalued PS

-1527.24